Home
Voronoi

Voronoi Market Share Analysis for August 2026

Voronoi

Health > Biotechnology and Pharmaceuticals

Domainvoronoi.io

Year Founded2015

Employees51 - 200

Annual Revenue$1M - $2M

Voronoi

Voronoi (including company regionals)

voronoi.io

See more website traffic and engagement information

Voronoi Revenue up to August 2026 is 1M - 2M

revenue generated by Voronoi top domains

Voronoi top domains revenue over 3 years

Revenue for Voronoi top domains

voronoi.io1M - 2M

See more with Sales Intelligence

Total visits to Voronoi's top domains

Understand Voronoi market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

voronoi.io7.8K

See more with Sales Intelligence

Avg. visit duration in Voronoi's top domains

Analyze Voronoi engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

voronoi.io00:01:57

See more with Sales Intelligence

Avg. pageviews on Voronoi's top domains

See how Voronoi keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

voronoi.io2.87

See more with Sales Intelligence

Voronoi top competitors by domain

Top similar sites in August 2026, ranked by their affinity

productlifegroup.comCompany NameProductLife GroupEmployees1001 - 5000HQFrance, SuresnesAnnual revenue$100M - $200MTotal visits20.7KJobs and Career > Jobs and Employment

Top technologies used by Voronoi

These are the website technologies, by industry, used by Voronoi top domains

Widget (6)

Twemoji

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Content Management System (2)

WordPress

More Technologies

7

See all

News & Signals from Voronoi

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsORIC Pharmaceuticals, Inc. partners with VORONOI, Inc..ORIC Pharmaceuticals has entered into an exclusive license agreement with Voronoi for the development of ORIC-114, a selective inhibitor targeting EGFR and HER2 exon 20 insertion mutations.